Table 1 Distribution of PROCR rs867186... | American Society of Hematology

Table 1

Distribution of PROCR rs867186 genotypes among cases and non-cases in studies of VTE and MI

Included study*	AA genotype				AG genotype				GG genotype				MAF†	Deviation from Hardy-Weinberg equilibrium
	Cases		Non-cases		Cases		Non-cases		Cases		Non-cases			Deviation from Hardy-Weinberg equilibrium
	n	%	n	%	n	%	n	%	n	%	n	%		χ²P value	REH (95% CI)‡
VTE
Medina 2004¹⁷	291	82	327	82	62	17	74	18	2	1	0	0	0.09	.04
Saposnik 2004³⁵	249	74	278	82	85	25	58	17	4	1	2	1	0.09	.58	1.23 (0.59-2.58)
Uitte de Willige 2004¹⁰	345	73	361	77	116	25	100	21	10	2	10	2	0.13	.33	0.83 (0.58-1.21)
Medina 2005⁴¹	77	81	145	80	17	18	35	19	1	1	1	1	0.10	.47	1.45 (0.52-4.10)
Navarro 2008⁹	58	69	128	86	24	29	21	14	2	2	0	0	0.07	.35
Pecheniuk 2008⁴⁶)	82	72	87	76	27	24	24	21	5	4	3	3	0.13	.40	0.74 (0.37-1.50)
Trégouët 2009–GWAS³⁰	309	75	1003	82	92	22	216	18	9	2	8	1	0.09	.32	1.21 (0.83-1.75)
Trégouët 2009–MARTHA³⁰	885	79	654	82	222	20	141	18	16	1	5	1	0.09	.38	1.23 (0.77-1.97)
Yamagishi 2009⁴⁵	417	84	844	83	72	15	158	16	7	1	14	1	0.09	.04	0.73 (0.53-0.99)
Chen 2011⁴⁷	49	75	63	89	15	23	7	10	1	2	1	1	0.06	.15	0.44 (0.13-1.52)
Heit 2011	978	77	1029	79	264	21	257	20	28	2	16	1	0.11	.99	1.00 (0.76-1.32)
MI
Ireland 2005–EDSC-EW¹⁸	33	65	231	85	17	33	37	14	1	2	4	1	0.08	.09	0.61 (0.34-1.10)
Ireland 2005–EDSC-IA¹⁸	63	55	222	64	48	42	108	31	3	3	19	5	0.21	.23	0.83 (0.62-1.12)
Ireland 2005–HIFMECH¹⁸	440	84	455	81	83	16	101	18	3	1	7	1	0.10	.60	0.89 (0.59-1.36)
Ireland 2005–NPHSII¹⁸	166	85	1883	82	26	13	387	17	4	2	14	1	0.09	.57	1.08 (0.84-1.38)
Medina 2008⁴⁸	606	88	554	79	80	12	142	20	3	0	1	0	0.10	.01	3.02 (1.12-8.16)
Schunkert 2011–ADVANCE³¹	221	79	262	84	55	20	49	16	2	1	1	0	0.08	.41	1.51 (0.55-4.20)
Schunkert 2011 CADomics³¹	1642	79	2324	79	409	20	589	20	25	1	37	1	0.11	.96	1.00 (0.84-1.20)
Schunkert 2011 deCODE CAD³¹	5509	83	22 711	82	1078	16	4640	17	51	1	244	1	0.09	.68	0.99 (0.92-1.06)
Schunkert 2011 GerMIFS I³¹	670	77	1225	77	184	21	344	22	11	1	23	1	0.12	.84	1.02 (0.81-1.29)
Schunkert 2011 GerMIFS II³¹	981	80	1007	78	227	19	265	21	14	1	15	1	0.11	.60	1.08 (0.81-1.43)
Schunkert 2011 GerMIFS III³¹	922	80	1359	78	222	19	360	21	13	1	29	2	0.12	.36	0.91 (0.73-1.12)
Schunkert 2011 MedStar³¹	369	83	721	82	76	17	148	17	2	0	6	1	0.09	.59	1.13 (0.73-1.73)
Schunkert 2011 MIGen³¹	1035	81	1151	82	224	18	240	17	12	1	14	1	0.10	.71	0.95 (0.71-1.27)
Schunkert 2011 OHGS1³¹	1207	82	1141	81	257	18	263	19	4	0	11	1	0.10	.33	1.17 (0.85-1.62)
IBC 50K CAD Consortium (European)⁴²§													0.10
IBC 50K CAD Consortium (South Asian)⁴²§													0.19

Included study*	AA genotype				AG genotype				GG genotype				MAF†	Deviation from Hardy-Weinberg equilibrium
	Cases		Non-cases		Cases		Non-cases		Cases		Non-cases			Deviation from Hardy-Weinberg equilibrium
	n	%	n	%	n	%	n	%	n	%	n	%		χ²P value	REH (95% CI)‡
VTE
Medina 2004¹⁷	291	82	327	82	62	17	74	18	2	1	0	0	0.09	.04
Saposnik 2004³⁵	249	74	278	82	85	25	58	17	4	1	2	1	0.09	.58	1.23 (0.59-2.58)
Uitte de Willige 2004¹⁰	345	73	361	77	116	25	100	21	10	2	10	2	0.13	.33	0.83 (0.58-1.21)
Medina 2005⁴¹	77	81	145	80	17	18	35	19	1	1	1	1	0.10	.47	1.45 (0.52-4.10)
Navarro 2008⁹	58	69	128	86	24	29	21	14	2	2	0	0	0.07	.35
Pecheniuk 2008⁴⁶)	82	72	87	76	27	24	24	21	5	4	3	3	0.13	.40	0.74 (0.37-1.50)
Trégouët 2009–GWAS³⁰	309	75	1003	82	92	22	216	18	9	2	8	1	0.09	.32	1.21 (0.83-1.75)
Trégouët 2009–MARTHA³⁰	885	79	654	82	222	20	141	18	16	1	5	1	0.09	.38	1.23 (0.77-1.97)
Yamagishi 2009⁴⁵	417	84	844	83	72	15	158	16	7	1	14	1	0.09	.04	0.73 (0.53-0.99)
Chen 2011⁴⁷	49	75	63	89	15	23	7	10	1	2	1	1	0.06	.15	0.44 (0.13-1.52)
Heit 2011	978	77	1029	79	264	21	257	20	28	2	16	1	0.11	.99	1.00 (0.76-1.32)
MI
Ireland 2005–EDSC-EW¹⁸	33	65	231	85	17	33	37	14	1	2	4	1	0.08	.09	0.61 (0.34-1.10)
Ireland 2005–EDSC-IA¹⁸	63	55	222	64	48	42	108	31	3	3	19	5	0.21	.23	0.83 (0.62-1.12)
Ireland 2005–HIFMECH¹⁸	440	84	455	81	83	16	101	18	3	1	7	1	0.10	.60	0.89 (0.59-1.36)
Ireland 2005–NPHSII¹⁸	166	85	1883	82	26	13	387	17	4	2	14	1	0.09	.57	1.08 (0.84-1.38)
Medina 2008⁴⁸	606	88	554	79	80	12	142	20	3	0	1	0	0.10	.01	3.02 (1.12-8.16)
Schunkert 2011–ADVANCE³¹	221	79	262	84	55	20	49	16	2	1	1	0	0.08	.41	1.51 (0.55-4.20)
Schunkert 2011 CADomics³¹	1642	79	2324	79	409	20	589	20	25	1	37	1	0.11	.96	1.00 (0.84-1.20)
Schunkert 2011 deCODE CAD³¹	5509	83	22 711	82	1078	16	4640	17	51	1	244	1	0.09	.68	0.99 (0.92-1.06)
Schunkert 2011 GerMIFS I³¹	670	77	1225	77	184	21	344	22	11	1	23	1	0.12	.84	1.02 (0.81-1.29)
Schunkert 2011 GerMIFS II³¹	981	80	1007	78	227	19	265	21	14	1	15	1	0.11	.60	1.08 (0.81-1.43)
Schunkert 2011 GerMIFS III³¹	922	80	1359	78	222	19	360	21	13	1	29	2	0.12	.36	0.91 (0.73-1.12)
Schunkert 2011 MedStar³¹	369	83	721	82	76	17	148	17	2	0	6	1	0.09	.59	1.13 (0.73-1.73)
Schunkert 2011 MIGen³¹	1035	81	1151	82	224	18	240	17	12	1	14	1	0.10	.71	0.95 (0.71-1.27)
Schunkert 2011 OHGS1³¹	1207	82	1141	81	257	18	263	19	4	0	11	1	0.10	.33	1.17 (0.85-1.62)
IBC 50K CAD Consortium (European)⁴²§													0.10
IBC 50K CAD Consortium (South Asian)⁴²§													0.19

Studies are identified by the lead author's last name, year of publication, study name (if a publication included more than 1 study), and reference number.

†

The minor allele (G) frequency (MAF) was calculated in controls or in the underlying cohort.

‡

The REH cannot be calculated in studies with 0 cases or controls with the GG genotype.

Genotype frequencies were not reported in the published article; however, the study authors state that the single-nucleotide polymorphism did not violate HWE in the controls (P > .0001).

View Large

This Feature Is Available To Subscribers Only